Checkpoint Inhibitors Versus TKI Therapy in HCC

Ghassan K. Abou-Alfa, MD; Amit Singal, MD; Mark H. O’Hara, MD; Manish R. Sharma, MD; A. Ruth He, MD, PhD; and Mark W. Karwal, MD, explore emerging immune-oncology agents that are being investigated for the treatment of hepatocellular carcinoma and consider their role in the context of other targeted agents.